According to FIGO 2023 endometrial cancer staging, which molecular classifier defines the MOST FAVOURABLE prognostic group?

• A Mismatch repair deficiency (MMRd)
• B p53 wild-type, no specific molecular profile (NSMP)
• C p53 abnormal (p53abn)
• D POLE mutation (POLEmut) ✓

Explanation

The FIGO 2023 endometrial cancer staging integrates molecular classifiers from the ProMisE and PORTEC systems. POLEmut (POLE-ultramutated) tumours have an excellent prognosis — even when high-grade — with 5-year survival exceeding 95%, and may avoid adjuvant therapy. MMRd tumours have intermediate prognosis and high response to immunotherapy (pembrolizumab). NSMP is also intermediate. p53abn (TP53-mutant, serous-like) has the worst prognosis. FIGO 2023 integrates Stage with molecular subtype to guide adjuvant treatment decisions.

Reference: Shaw's Textbook of Gynaecology, 17th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.